

	Level	High	Low	<i>p</i>
<i>n</i>		52	39	
Age at initial pathologic diagnosis				
		64.63 (11.35)	67.00 (11.02)	0.322
(mean (SD))				
gender (%)	Female	21 (40.4)	22 (56.4)	0.193
	Male	31 (59.6)	17 (43.6)	
race (%)	Not Evaluated	0 (0.0)	1 (2.6)	0.58
	Asian	5 (9.6)	3 (7.7)	
	Black or African American	3 (5.8)	1 (2.6)	
	White	44 (84.6)	34 (87.2)	
Ajcc pathologic tumor stage (%)	Discrepancy	0 (0.0)	2 (5.1)	0.346
	Stage IA	1 (1.9)	2 (5.1)	
	Stage IB	2 (3.8)	4 (10.3)	
	Stage IIA	11 (21.2)	6 (15.4)	
	Stage IIB	36 (69.2)	25 (64.1)	
	Stage III	1 (1.9)	0 (0.0)	
	Stage IV	1 (1.9)	0 (0.0)	
Clinical stage (%)		52 (100.0)	39 (100.0)	NA
Histological type (%)	Discrepancy	0 (0.0)	1 (2.6)	0.448

	Pancreas-Adenocarcinoma-Other Subtype	4 (7.7)	5 (12.8)	
	Pancreas-Adenocarcinoma Ductal Type	46 (88.5)	30 (76.9)	
	Pancreas-Colloid (mucinous non-cystic)			
	Carcinoma	2 (3.8)	2 (5.1)	
	Pancreas-Undifferentiated Carcinoma	0 (0.0)	1 (2.6)	
Histological grade (%)	G1	6 (11.5)	5 (12.8)	0.184
	G2	35 (67.3)	18 (46.2)	
	G3	10 (19.2)	13 (33.3)	
	G4	0 (0.0)	2 (5.1)	
	GX	1 (1.9)	1 (2.6)	
Initial pathologic dx year				
(mean (SD))		2011.12 (1.60)	2011.08 (2.15)	0.927
Menopause status (%)		52 (100.0)	39 (100.0)	NA
Birth days to (mean (SD))		-23804.62 (4158.43)	-24650.90 (4017.67)	0.332
Vital status (%)	Alive	13 (25.0)	19 (48.7)	0.034
	Dead	39 (75.0)	20 (51.3)	
Tumor status (%)		6 (11.5)	4 (10.3)	0.2
	Tumor free	10 (19.2)	14 (35.9)	

	With tumor	36 (69.2)	21 (53.8)	
Last contact days to (mean (SD))		720.08 (526.21)	840.05 (526.66)	0.531
Death days to (mean (SD))		462.00 (381.92)	492.45 (404.02)	0.777
Cause of death (%)		21 (40.4)	21 (53.8)	0.731
	Other malignancy	1 (1.9)	1 (2.6)	
	Other, non-malignant disease	2 (3.8)	2 (5.1)	
	Other, specify	1 (1.9)	0 (0.0)	
	Pancreatic Cancer	26 (50.0)	14 (35.9)	
	Surgical Complications	1 (1.9)	1 (2.6)	
New tumor event type (%)		24 (46.2)	23 (59.0)	0.298
	Distant Metastasis	17 (32.7)	12 (30.8)	
	Locoregional Recurrence	10 (19.2)	3 (7.7)	
	Locoregional Recurrence Distant Metastasis	0 (0.0)	1 (2.6)	
	New Primary Tumor	1 (1.9)	0 (0.0)	
New tumor event site (%)		28 (53.8)	23 (59.0)	0.604
	Liver	8 (15.4)	8 (20.5)	
	Lung	3 (5.8)	3 (7.7)	

	Other, specify	9 (17.3)	4 (10.3)	
	Peritoneal Surfaces	3 (5.8)	0 (0.0)	
	Tumor Bed	1 (1.9)	1 (2.6)	
New tumor event site other (%)		44 (84.6)	35 (89.7)	0.495
	Adrenal and right buttock	1 (1.9)	0 (0.0)	
	bone	0 (0.0)	1 (2.6)	
	Liver/lung	1 (1.9)	0 (0.0)	
	Lung and Liver	1 (1.9)	0 (0.0)	
	malignant ascites	1 (1.9)	0 (0.0)	
	Omentum	1 (1.9)	0 (0.0)	
	Omentum, Peritoneal surface, Non			
	regional Lymph nodes	1 (1.9)	0 (0.0)	
	perigastric mass	0 (0.0)	1 (2.6)	
	Regional LNs	1 (1.9)	0 (0.0)	
	retroperitoneal recurrence around the			
	supramesenteric artery and vein and some	0 (0.0)	1 (2.6)	
	para aortic nodes			
	Retroperitoneum	1 (1.9)	0 (0.0)	
	Superior Mesenteric Artery	0 (0.0)	1 (2.6)	

New tumor event dx days to			
(mean (SD))	380.25 (352.88)	478.88 (391.54)	0.396
Treatment outcome first course (%)	1 (1.9)	1 (2.6)	0.866
Discrepancy	2 (3.8)	1 (2.6)	
Unknown	5 (9.6)	6 (15.4)	
Complete Remission/Response	20 (38.5)	17 (43.6)	
Partial Remission/Response	3 (5.8)	1 (2.6)	
Progressive Disease	17 (32.7)	12 (30.8)	
Stable Disease	4 (7.7)	1 (2.6)	
Margin status (%)	52 (100.0)	39 (100.0)	NA
Residual tumor (%)	52 (100.0)	39 (100.0)	NA
OS (mean (SD))	0.75 (0.44)	0.51 (0.51)	0.019
OS.time (mean (SD))	526.52 (431.93)	661.79 (493.94)	0.168
DSS (mean (SD))	0.63 (0.49)	0.39 (0.50)	0.027
DSS.time (mean (SD))	526.52 (431.93)	661.79 (493.94)	0.168
DFI (mean (SD))	0.53 (0.51)	0.18 (0.39)	0.029
DFI.time (mean (SD))	468.74 (446.80)	859.06 (592.80)	0.031
PFI (mean (SD))	0.75 (0.44)	0.56 (0.50)	0.063
PFI.time (mean (SD))	418.31 (380.03)	557.41 (484.59)	0.128

Redaction (%)		52 (100.0)	39 (100.0)	NA
Risk (%)	High	52 (100.0)	0 (0.0)	<0.001
	Low	0 (0.0)	39 (100.0)	